It has been reported that CMTM5 acted as a tumour-suppressor gene and was specifically down-regulated in many human cancers, such as cervical carcinoma [8], pancreatic cancer [9], myeloid leukemia [10], ovarian cancer [11], oral squamous cell carcinoma (OSCC) [12] and prostate cancer [13]. Here, CMTM5 is linked to prostate carcinoma.